Tag Archive for: immunology

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer

/in

Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalities AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses Lund, Sweden, […]

Read more

Medicxi Announces $40m investment in D3 Bio

/in

Investment will support development of a differentiated pipeline in oncology Most advanced asset is D3S-001 with potential to be a best-in-class KRAS G12C inhibitor Data on lead asset D3S-001 to be presented at AACR on 8 April 2024  8 April 2024, London, Geneva & Jersey: Medicxi, a leading European life sciences investment firm, today announces an investment of […]

Read more

Poolbeg Pharma – POLB 001 LPS Challenge Trial Data to be Presented at IUIS

/in

POLB 001 – a potential blockbuster immunomodulator 16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International […]

Read more